Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1984 1
1985 1
1986 5
1987 9
1988 21
1989 23
1990 47
1991 46
1992 49
1993 54
1994 58
1995 91
1996 49
1997 73
1998 52
1999 67
2000 69
2001 89
2002 81
2003 95
2004 95
2005 109
2006 89
2007 95
2008 99
2009 104
2010 104
2011 98
2012 88
2013 91
2014 84
2015 73
2016 60
2017 63
2018 41
2019 36
2020 24
2021 11
Text availability
Article attribute
Article type
Publication date

Search Results

2,173 results
Results by year
Filters applied: . Clear all
Page 1
A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d.
Davidson MH, Palmisano J, Wilson H, Liss C, Dicklin MR. Davidson MH, et al. Clin Ther. 2003 Nov;25(11):2738-53. doi: 10.1016/s0149-2918(03)80330-2. Clin Ther. 2003. PMID: 14693301 Clinical Trial.
RESULTS: A total of 838 patients (476 men, 362 women; mean [SD] age, 59 [12] years) were included in the study. Lovastatin 20 and 40 mg/d significantly reduced mean LDL-C compared with the same dosages of fluvastatin. TC and the LDL-C:HDL-C ratio decreased more with lov
RESULTS: A total of 838 patients (476 men, 362 women; mean [SD] age, 59 [12] years) were included in the study. Lovastatin 20 and 40 …
A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk.
Vinayak S, Schwartz EJ, Jensen K, Lipson J, Alli E, McPherson L, Fernandez AM, Sharma VB, Staton A, Mills MA, Schackmann EA, Telli ML, Kardashian A, Ford JM, Kurian AW. Vinayak S, et al. Breast Cancer Res Treat. 2013 Nov;142(2):389-98. doi: 10.1007/s10549-013-2739-z. Epub 2013 Oct 29. Breast Cancer Res Treat. 2013. PMID: 24166281 Free PMC article. Clinical Trial.
Participants received 40 mg of lovastatin orally twice daily for 6 months. We evaluated the following biomarkers before and after lovastatin use: breast duct cytology (primary endpoint), serum lipids, C-reactive protein, insulin-like growth factor-1, IGF binding pro …
Participants received 40 mg of lovastatin orally twice daily for 6 months. We evaluated the following biomarkers before and after …
Lovastatin and simvastatin prevention studies.
Jones PH. Jones PH. Am J Cardiol. 1990 Sep 18;66(8):39B-43B. doi: 10.1016/0002-9149(90)90439-8. Am J Cardiol. 1990. PMID: 2206035 Review.
Recently, a new class of hypolipidemic agents has been shown to be extremely effective in lowering total and low-density lipoprotein cholesterol levels. These drugs, including lovastatin and simvastatin, competitively inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase …
Recently, a new class of hypolipidemic agents has been shown to be extremely effective in lowering total and low-density lipoprotein cholest …
Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome.
Thurman AJ, Potter LA, Kim K, Tassone F, Banasik A, Potter SN, Bullard L, Nguyen V, McDuffie A, Hagerman R, Abbeduto L. Thurman AJ, et al. J Neurodev Disord. 2020 Apr 22;12(1):12. doi: 10.1186/s11689-020-09315-4. J Neurodev Disord. 2020. PMID: 32316911 Free PMC article. Clinical Trial.
BACKGROUND: The purpose of this study was to conduct a 20-week controlled trial of lovastatin (10 to 40 mg/day) in youth with fragile X syndrome (FXS) ages 10 to 17 years, combined with an open-label treatment of a parent-implemented language intervention (PILI), delivered …
BACKGROUND: The purpose of this study was to conduct a 20-week controlled trial of lovastatin (10 to 40 mg/day) in youth with fragile …
Extended clinical safety profile of lovastatin.
Mantell G, Burke MT, Staggers J. Mantell G, et al. Am J Cardiol. 1990 Sep 18;66(8):11B-15B. doi: 10.1016/0002-9149(90)90435-4. Am J Cardiol. 1990. PMID: 2206031 Review.
Lovastatin has been available for prescription use in the United States for about 20 months (as of June 1989). ...At least 645 patients have received lovastatin for more than 3 years. There are new data from a recently completed 1 year, placebo-controlled trial in 8
Lovastatin has been available for prescription use in the United States for about 20 months (as of June 1989). ...At least 645 patien
A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group.
[No authors listed] [No authors listed] Am J Cardiol. 1993 Apr 1;71(10):810-5. doi: 10.1016/0002-9149(93)90829-2. Am J Cardiol. 1993. PMID: 8456759 Clinical Trial.
A randomized, controlled, double-blind trial in 672 hypercholesterolemic patients evaluated the efficacy and safety profile of lovastatin and pravastatin across their usually recommended dosage ranges (lovastatin 20 to 80 mg/day and pravastatin 10 to 40 mg/day). Aft …
A randomized, controlled, double-blind trial in 672 hypercholesterolemic patients evaluated the efficacy and safety profile of lovastatin
Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC, Boudoulas H. Kontopoulos AG, et al. Coron Artery Dis. 1996 Nov;7(11):843-50. doi: 10.1097/00019501-199611000-00009. Coron Artery Dis. 1996. PMID: 8993943 Clinical Trial.
2,173 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page